secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2025-08-26T23:59:59+00:00
Accession:  0001213900-25-080484
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies terminates $15M equity line; $4.2M raised, burn reduced
--------------------------------------------------------------------

- Terminated ELOC Purchase Agreement with Square Gate effective Aug 26, 2025; no outstanding borrowings or fees.
- Recent warrant exercise exchange provided $4.2M gross proceeds to fund operations into mid-2026.
- Projected monthly burn in H2 2025 significantly lower than H1 2025, completing Phase 2b and Phase 1b treatment phases.
- Company focusing capital on advancing OST-HER2 toward approval and analyzing OST-504 prostate cancer data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025080484/0001213900-25-080484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025080484/ea0254579-8k_ostherap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-080484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer